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Abstract: Epothilones are a new class of antimicrotubule agents currently in clinical trials. Their 
chemical structures are distinct from taxanes and are more amenable to synthetic modiﬁ  cation. 
Six epothilones have been studied in preclinical and clinical trials: patupilone (epothilone B), 
ixabepilone (BMS247550), BMS 310705, sagopilone (ZK-EPO), KOS-862 (epothilone D), and 
KOS-1584. In vitro data have shown increased potency in taxane-sensitive and taxane-resistant 
cancer cell lines. This enhanced cytotoxic effect has been attributed to epothilone being a poor 
substrate for p-glycoprotein drug resistance protein and having high afﬁ  nity to the various β 
tubulin isoforms. Phase I clinical data have shown different dose-limiting toxicities for each of 
the epothilones. These effects are drug speciﬁ  c, dose speciﬁ  c, and schedule of administration 
speciﬁ  c. While diarrhea and myelosuppression are the dose-limiting toxicities for patupilone 
and BMS 310705, respectively, neurologic toxicity, as seen with taxanes, is the dose-limiting 
toxicity of ixabepilone, sagopilone, and KOS-862. In an effort to decrease neurologic toxicity, 
investigators have modiﬁ  ed dosing schedules with limited success. Ixabepilone has the most 
mature clinical results with published phase II and III data, and regulatory approval for clinical 
use in the treatment of breast cancer. Ixabepilone has also been combined with other anticancer 
agents and has regulatory approval in combination with capecitabine for heavily treated breast 
cancer.
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History
Drugs that target tubulin are active in human malignant disease and are an essential 
component of medical treatment of these diseases (Budman 2005, Pellegrini and 
Budman 2005). Of this class of agents, a variety of active drug structures have been 
identiﬁ  ed, with the vinca alkaloids, the taxanes, and the epothilones achieving regula-
tory approval for cancer treatment. As a result, pharmaceutical research on compounds 
that interfere with tubulin function has concentrated on agents which might have 
enhanced efﬁ  cacy or reduced toxicity. A current Medline search for “tubulin binding 
drugs” yielded 430 references. An analogous search of the National Institutes of Health 
Clinical Trials Registry, http://clinicaltrials.gov, using the phrase “epothilone” lists 
108 clinical studies in patients with malignant disease.
The epothilones were originally discovered in 1987 from the fermentation of soil 
bacteria found on the banks of the Zambesi River in Africa (Gerth et al 1996; Lee et al 
2008). A myxobacterium, Sorangium cellulosum, was noted to produce biologically 
active substances. One chemical isolate, epothilone A, was noted to be highly cytotoxic 
(inhibitory concentration at 50% activity, IC50 = 0.05 μM) in vitro when applied to the 
human T-24 bladder carcinoma cell line (Gerth et al 1996).
Natural products are a well recognized source of novel agents for anticancer 
development and such drugs are usually selected on the basis of functional screening 
(Shah and Kaye 2003). Epothilone, a macrolide compound, was selected for further Biologics: Targets & Therapy 2008:2(4) 790
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development on the basis of demonstrated paclitaxel-like 
properties during preclinical screening of compounds binding 
to tubulin. Bollag et al (1995) used a novel microtubule 
ﬁ  ltration assay to rapidly screen large numbers of compounds 
to select agents which induced tubulin polymerization. 
Electron microscopy differentiated true polymerization 
induced by the screened compounds from nonspeciﬁ  c protein 
aggregation. Of 7000 test samples screened, 6% of plant 
extracts and 0.5% of other sources (marine, insect, microbial) 
screened positive, one of them being epothilone. Although 
other natural products with similar in vitro taxane-like 
activity were isolated, epothilone’s successful development 
can be credited to its easy synthesis in bulk from fermentation 
and its structure being amenable to modiﬁ  cation (Bollag et al 
1995). The original structures were epothilone A and B. 
Epothilones derived from fermentation are classiﬁ  ed as 
either epoxides on the presence of an epoxide structure at 
C-12–C-13 (epothilones A, B, E, F) or oleﬁ  ns (epothilone 
C, D) (Fumoleau et al 2007). Semi-synthetic derivatives 
have subsequently been developed to enhance pharmacologic 
properties. Epothilones demonstrated greater cytotoxicity 
than paclitaxel with an IC50 in the low nanomolar range in 
a variety of tumor cell lines (Bollag et al 1995; Chou et al 
1998; Lee et al 2001; Fumoleau et al 2007). The six agents 
that have reached clinical trials in man are discussed below 
(Table 1).
Chemistry
The National Institutes of Health maintains a web site, 
PubChem (http://pubchem.ncbi.nlm.nih.gov) which is 
invaluable for information on chemical, preclinical activity, 
and toxicology of drugs. Twelve epothilones are listed on 
this web site. Epothilones are structurally less complex 
and have a ring structure unrelated to that of paclitaxel. 
The critical structure is the macrolide ring with a thiazole-
containing side chain and a ketone (Figure 1). The only 
structural difference between epothilone A and B is that 
epothilone B (patupilone) has a methyl group at position 
C12 (Figure 1). Patupilone is more hydrophilic than 
epothilone A (XlogP, the partition distribution coefﬁ  cient 
between water and octanol, is 2.1 vs 1.7 respectively). This 
small modiﬁ  cation increases microtubule stabilization such 
that patupilone is twice as potent as epothilone A (Goodin 
et al 2004; Cortes and Baselga 2007). Epothilone A has poor 
pharmacologic properties with loss of structural stability in 
animal plasma which led to the agent being dropped from 
further studies (Lee et al 2008).
Structural modiﬁ  cations have also been made to improve 
drug solubility and in some cases to negate the need for 
solubilization in vehicles that may cause hypersensitivity 
reactions. Ixabepilone is a second-generation patupilone 
derivative with an azide group in place of oxygen on 
position 16 of the macrolide ring (Figure 1). Ixabepilone is 
more resistant to degradation by carboxylesterase than the 
parent compound (Goodin et al 2004). BMS-310705 is a 
water-soluble derivative of patupilone with a substitution of 
the hydroxyl group with an amino group in the C21 position 
of the methythiazole side chain. An analog of patupilone, 
ABJ879 (2–desmethyl-20-methylsulfanyl-Epo-B), is highly 
active in a taxane-resistant cervical cancer model and did 
reach phase I studies. No more information is available 
to date (Altmann and Memmert 2008). Modiﬁ  cations at 
speciﬁ  c positions on the macrolide ring enhance the in 
vitro activity. Sagopilone (ZK-EPO, ZK-219447) is the 
only fully synthetic third generation analog of patupilone, 
assembled from three building blocks (Alexander et al 
2008). This drug was selected from a variety of analogs 
for further development because of its high potency in 
preclinical tumor models and its solubility in aqueous 
solutions (Klar et al 2006).
Desoxyepothilone B (KOS-862, epothilone D) lacks 
the C12-13 epoxide and is more potent than epothilone 
A in preclinical models utilizing ovarian cell lines that 
are resistant to taxanes (Nicolaou et al 1997; Goodin et al 
2004). Hence, the epoxide ring is not a requirement for 
anticancer effect (Altmann 2005). A second generation 
Table 1 Epothilone entities that have been studied clinically
Agent Origin Solvent used clinically Dose-limiting toxicity
Patupilone Natural product Polyethylene glycol 300 diarrhea
BMS-310705 2nd generation epothilone B aqueous hematologic/hyponatremia
Ixabepilone 2nd generation epothilone B Cremophor EL hematologic/neurologic
Sagopilone 3rd generation epothilone B aqueous neurologic
Epothilone D Lacks C 12–13 epoxide of B Cremophor EL neurologic
KOS-1584 2nd generation epothilone D aqueous hepatotoxic/diarrheaBiologics: Targets & Therapy 2008:2(4) 791
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epothilone D analog, KOS 1584, has also been shown 
to have greater in vitro potency than patupilone or 
epothilone D (Fumoleau et al 2007).
Structure/function activity
Analogous to paclitaxel, epothilones bind to a common 
binding site on β-tubulin. A preclinical study in resistant 
cell lines also noted that both taxanes and epothilones share a 
common tertiary structure for binding to tubulin even though 
their chemical structures are distinct (Giannakakou et al 
2000). The binding afﬁ  nity of epothilone A to tubulin is of the 
same order of magnitude as the binding afﬁ  nity of paclitaxel 
to tubulin based on competition assays. The 50% inhibitory 
concentration for displacement of 100 nM of (3H) paclitaxel 
from the tubulin binding site was 3.6 μM for paclitaxel, 
2.3 μM for epothilone A, and 3.3 μM for patupilone (Nettles 
et al 2004). These studies indicate that taxanes and epothilones 
bind at or near the same site (Kowalski et al 1997).
However, other studies have suggested that the interac-
tions by the pharmacophore of each agent within the binding 
pocket are not identical (Nettles et al 2004). These differences 
may reﬂ  ect the differences in experimental conditions used 
to elucidate drug function (Reese et al 2006). In vitro studies 
of epothilone A bound to α,β tubulin in zinc-stabilized sheets 
demonstrate that epothilone A and paclitaxel share only 
one polar contact at C-7-OH while the thiazole side chain 
of epothilone binds to a different region of β-tubulin not 
occupied by paclitaxel (Nettles et al 2004; Lee and Swain 
2008). In addition, the methyl group at C12 seems to enhance 
a hydrophobic interaction between patupilone and β tubulin 
that allows patupilone to be more potent than epothilone A 
(Kowalski et al 1997).
Nuclear magnetic resonance spectroscopy, electron 
crystallography, and molecular modeling have revealed 
further binding interactions of the epothilones with tubu-
lin. The 16 member ring and part of the side chain reside 
within a hydrophobic region of β-tubulin. In the case of 
epothilone A, hydrogen bonds bind C1=O, C3-OH, C5=O, 
and C7-OH to tubulin at threonine 274, arginine 278, and 
arginine 282 residues of the M-loop. Hydrophobic inter-
actions occur at the C3 to C11 portion of epothilone A 
(Nettles et al 2004). As previously noted (Altmann 2005), 
although initial studies indicated that the C12-13 epoxide 
was required for localizing the epothilone onto its tubulin 
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Figure 1 Chemical structures of the epothilones in clinical development. Reproduced from Alexander E, Rosa E, Bolos J, et al. 2008. Sagopilone. Drugs Future, 33:496–505. 
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target, more recent ﬁ  ndings demonstrate that this moiety is 
not necessary as epothilone D is highly active as a tubulin 
binder (Nicolaou et al 1997).
Preclinical functional activity
Microtubules are present in all eukaryotes and are essential 
for the intracellular structure, cell division, and intracellular 
transport (Esteve et al 2007). These processes are regulated 
by polymerization and disassembly of the microtubule poly-
mers. Disruption of these processes targets the cell for G2/M 
phase arrest resulting in apoptosis (Bhat and Setaluri 2007). 
Epothilones promote tubulin polymerization in vitro in the 
absence of microtubule associated proteins or guanosine 
triphosphate. These agents also prevent depolymerization 
of the microtubulin structure in the presence of calcium 
(Bollag et al 1995; Altmann et al 2004). Epothilones can 
also induce apoptosis at concentrations that do not cause 
mitotic cell cycle arrest. This cytotoxic effect is believed 
to be caused by disruption in the dynamic equilibrium 
between the intracellular pool of basic tubulin components 
(α, β heterodimers) and the microtubule polymer (Chen and 
Horwitz 2002; Goodin et al 2004).
Using human MDA-MB-435 cells and fluorescence 
microscopy, investigators have noted a biologic difference 
in the spindle pole effects of epothilone A and of patupi-
lone (Sakaushi et al 2008). These results suggest that small 
changes in the epothilone structure may have major differ-
ences in biological effect. Patupilone has recently been noted 
to cause mitochrondrial collapse with release of reactive 
oxygen species in sensitive cells thus leading to apoptosis 
(Khawaja et al 2008). Hence, these drugs have potent apop-
totic promoting effects.
In vitro data demonstrate that patupilone at a concentra-
tion of 1 nmol/L has antiangiogenic properties when assayed 
using a human umbilical vein endothelial cell culture (Bijman 
et al 2006). The antiangiogenic activity has been related to 
interruption of microtubule dependent control of HIF-1α 
(hypoxia inducible factor 1α) translation (Escuin et al 2005). 
This anti-angiogenesis data suggests that these substances 
could potentially kill malignant cells at subtoxic concentra-
tions in vivo by an alternative mechanism.
Attractive features of epothilones include their potency 
relative to taxanes and their activity in both taxane sensitive 
and in resistant cell lines (Kowalski et al 1997; Nicolaou et al 
1997; Chou et al 1998; Goodin et al 2004; Mok et al 2006; 
Lee and Swain 2008) (Table 2). Epothilones have shown 
activity in ovarian, breast, lung, colon, prostate, squamous 
cell, ﬁ  broblast, and leukemia cell lines (Goodin et al 2004). 
Ixabepilone demonstrated signiﬁ  cant activity against the 
pediatric tumors – brain tumors, neuroblastoma, osteosar-
coma, rhabdomyosarcoma, and Wilm’s tumor – when grown 
in a murine model (Peterson et al 2005).
Patupilone has 3- to 20-fold higher in vitro cytotoxic 
potency compared with paclitaxel. In hepatocellular carci-
noma cell lines, patupilone was 4 to 19 times more potent 
than docetaxel or paclitaxel (Table 2) (Mok et al 2006). 
Ixabepilone, a patupilone analog, has been shown to be 2.5 
times more potent than paclitaxel in some cell lines (Table 2). 
In addition, ixabepilone has enhanced metabolic stability 
compared to the natural compounds (Lee et al 2001). 
Sagopilone, a synthetic patupilone analogue, acts in a taxane-
like manner but is more cytotoxic than other epothilone 
derivatives in development (Hoffmann et al 2008). This 
analog demonstrates activity in taxane-resistant cell lines 
(Hoffmann et al 2008). Recent in vitro studies have noted 
that sagopilone is rapidly taken up into A549 epidermoid 
nonsmall cell lung cancer cells with localization of drug into 
the cytoskeleton and accelerated tubulin polymerization com-
pared with paclitaxel or patupilone (Hoffmann et al 2008).
P-glycoprotein (also known as MDR) is an active 
drug efflux pump that results in cellular resistance to 
many cytotoxic agents. Epothilones are poor substrates 
for P-glycoprotein and are cytotoxic in cell lines that 
express high levels of P-glycoprotein (Lehne 2000). The 
epothilones can demonstrate an order of magnitude more 
cytotoxic effect at a given dose compared to paclitaxel 
(Table 2) (Chou et al 1998). As recent genomic data has 
determined that P-glycoprotein is over expressed in clinical 
samples of human Her2/neu+ breast cancer, these agents 
may be of particular value in this subset of patients (O'Brien 
et al 2008). The different epothilones demonstrate vary-
ing susceptibility to P-glycoprotein mediated resistance. 
ZK-EPO is not a substrate for this pump resistance protein 
(Stupp et al 2008). This drug is also highly active in cell 
lines expressing P-glycoprotein efﬂ  ux pumps (Hoffmann 
et al 2008). Epothilone D is highly active in both taxane 
sensitive and taxane resistant cell lines (Lee and Swain 
2008), while ixabepilone (BMS-247550) appears to be the 
most affected by P-glycoprotein expression but less so than 
paclitaxel (Table 2). Ixabepilone is 108 to 529 times more 
potent than taxanes or doxorubicin in the P-glycoprotein 
expressing hepatocellular carcinoma cell line SNU-449 
(Mok et al 2006). While in vitro studies show patupilone to 
be potent, animal xenograft models have shown increased 
toxicity and a narrower therapeutic index of B compared 
with epothilone D, suggesting a disassociation between the Biologics: Targets & Therapy 2008:2(4) 793
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ﬁ  ndings in cell lines and data from animal models (Chou 
et al 1998).
Through molecular modeling, microtubulin stabilizing 
agents have been found to have different affinities to 
β-tubulin isoforms. Paclitaxel has more afﬁ  nity to βI than 
to the βIII isoform (Magnani et al 2006). Increased βIII 
isoform expression is one mechanism of increased resistance 
to paclitaxel (Magnani et al 2006; Seve et al 2005, 2008). In 
contrast, epothilone A has the same afﬁ  nity for both isoforms 
(Magnani et al 2006).
Tubulin mutations are one cause of drug resistance in 
cultured cell lines as the target of these drugs is altered. 
Single point mutations in β-tubulin near the M loop at the 
nucleotide binding site and at the COOH terminus have been 
noted in some cancer cell lines. These sites are critical for the 
stabilization of microtubules. Point mutations in β-tubulin 
that confer resistance to epothilones are also associated with 
resistance to paclitaxel (Goodin et al 2004). One clinical 
study of 49 patients with nonsmall cell lung cancer suggested 
that paclitaxel resistance is associated with β-tubulin muta-
tions (Monzo et al 1999). The signiﬁ  cance of this ﬁ  nding is 
unclear, as tubulin mutations seem to be a rare occurrence 
in most human tumors (Berrieman et al 2004). In addition, 
tubulin mutations detected in non-small cell lung cancer 
samples isolated from patients were determined to be due 
to contamination of the genomic assay by ampliﬁ  cation 
of pseudogenes which share homology. These resistance 
mutations therefore were not present in clinical specimens 
(Noguchi 2006).
Tubulin binding agents can activate the steroid and 
xenobiotic receptor, also known as the human pregnane 
X receptor. Pregnane X receptor is known to be a master 
switch in drug resistance. Activation of this pathway leads to 
enhanced expression of cytochrome CYP3A4 in both tumor 
cell lines and in mice which enhances metabolic degradation 
of drugs thus resulting in drug resistance (Mani et al 2005). 
This effect has been seen with epothilones as well as with 
taxanes (Mani et al 2005).
Pharmacokinetics
Phase I data have evaluated pharmacokinetic parameters 
using various dosing schedules (Table 3). The Cpmax 
(maximal concentration of drug in the plasma) of these agents 
reaches the microgram per milliliter level in some of the 
schedules. A high volume of distribution is also commonly 
seen, suggesting high tissue binding. The half-lives of the 
various analogs varies from 7 to 89 hours and seems to differ 
depending upon the compound studied (Table 3). Apart from Biologics: Targets & Therapy 2008:2(4) 795
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differences in the drug structures, the pharmacokinetic and 
pharmacodynamic effects in man may be partly attributed 
to the solvent required for clinical administration of drug. 
Some of these agents are poorly soluble in aqueous solutions 
and therefore need a co-solvent (Table 1) which may perturb 
drug distribution and elimination.
BMS-310705 is a water soluble patupilone derivative 
and thus has the advantage of not requiring premedications 
to prevent reactions to solvent (Table 1) (Sessa et al 2007). 
Sagopilone, is also water soluble (Alexander et al 2008). 
Other formulations, such as ixabepilone and epothilone D, 
are formulated in polyoxyethylated castor oil and require 
prophylactic histamine-1 and histamine-2 blockers in order 
to avert hypersensitivity reactions induced by the solvents 
(Table 1). These adverse effects were previously well 
described for paclitaxel (Markman 2003).
Both patupilone and ixabepilone are metabolized by 
the liver. Excretion studies of radiolabeled ixabepilone 
found 52% of label excreted in the feces and 25% in the 
urine (Beumer et al 2007). Therefore liver dysfunction may 
affect clearance of the active drug. There are interpatient 
variabilities in drug disposition, especially with ixabepilone 
which is a substrate of cytochrome CYP3A4 (Goel et al 
2008). Incubation of ixabepilone in human liver micro-
somes with different cytochrome inhibitors demonstrated 
that metabolism of ixabepilone was inhibited by 90% with 
a potent CYP3A4 inhibitor (ketoconazole). In humans, 
co-administration of ketoconazole with ixabepilone increased 
plasma AUC0 −∞ (total drug exposure in the plasma) by 79% 
with a small increase in Cpmax. In this dose ranging study, 
the maximum tolerated dose was decreased from 30 mg/m2 
in patients with normal hepatic function to 25 mg/m2 in 
the presence of ketoconazole with dose-limiting toxicities 
of fatigue, neutropenia, mucositis, diarrhea, and febrile 
neutropenia (Goel et al 2008). In vitro studies indicate that 
patupilone is a weak inhibitor of CYP2C9, but a phase I study 
with warfarin did not show signiﬁ  cant drug-drug interaction 
(Takimoto et al 2008).
Table 3 Reported pharmacological parameters in the human phase I studies
Drug Investigator Cp ( mg/mL) Vd (L) Clearance (L/h) T1/2 (hours)
Patupilone 
(Epothilone B)
(Rubin et al 2005) 13 89
(Reid et al 2008): 10 mg/m2 
with normal hepatic 
function or 5 mg/m2 
with hepatic dysfunction
“similar values”a “similar values”a “similar values”a
BMS310705 (Mekhail et al 2003) 40 mg/m2 = 3936 ng/mL Vss 443 L/m2 277 mL/min/m2 42
(Sessa et al 2003) 5 mg/m2 = 313 ng/mL 133 L/m2 16 L/h/m2 7
25 mg/m2 = 1680 ng/mL 393 L/m2 19 L/h/ m2
Ixabepilone (Hao et al 2002) Vss-759.4 L/m2 25.8 L/h/m2 39.1
(Shimizu et al 2008) 15 mg/m2 = 62 ng/mL Vss = 1910 L 49 L/h 36
30 mg/m2 = 195 ng/mL 1759 L 43 L/h 43
40 mg/m2 = 313 ng/mL 1171 L 32 L/h 43
(Faivre et al 2008) 15 mg/m2 = 96–114 ng/mL 475–677 L 37–46 L/h 12–17
20 mg/m2 = 186–193ng/mL 429–526 L 30–32 L/h 13–17
25 mg/m2 = 171 ng/mL 755 L 29 L/h 25
30 mg/m2 = 261 ng/mL 595 L 37 L/h 16
Epothilone D (Spriggs et al 2003) 16 mg/m2 to 626 ng/mL 121 L/m2 10 L/h/m2 9
32 mg/m2 to 1623 ng/mL
64 mg/m2 to 2215 ng/mL
(Holen et al 2004) 4 mg/h = 200 ng/mL 96 L/m2 7 L/h/m2 10
KOS1584 (Piro et al 2003) 95 L/m2 5 L/h/m2 10
(Villalona-Calero et al 
2006)
8.5 mg/m2 = 78 ng/mL 741 L 30 L/h 18
(Stopeck et al 2006; 
Stopeck et al 2007)
5 mg/m2 = 122 ng/mL 504 L 20 L/h 19
aNo difference in pharmacokinetic parameters in normal and mild hepatic dysfunction with dose reduction.Biologics: Targets & Therapy 2008:2(4) 796
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Pharmacodynamics
At present, there is no way to predict the effectiveness of 
these drugs in clinical medicine. Surrogate markers of efﬁ  -
cacy and toxicity are needed. There are ongoing studies to 
correlate clinical response with microtubule bundle forma-
tion, tumor expression of microtubule stabilizing proteins, 
and post-translational changes in α tubulin (Pusztai 2007). 
Since epothilones have effects at concentrations lower than 
needed for microtubule bundle formation, the presence of 
microtubule formation may not serve as an effective surrogate 
marker.
In humans, microtubule bundle formation in peripheral 
blood mononuclear cells increased 1 hour after ixabepilone 
administration. Of note, there were different time courses 
of microtubule bundle formation in peripheral blood mono-
nuclear cells compared with tumor cells, suggesting dif-
ferential uptake and clearance (Mani et al 2004; Mani et al 
2007; Lee and Swain 2008). Preliminary data did not indicate 
any change in efﬁ  cacy in a mouse model with βIII isoform 
expression (Pusztai 2007). Increased expression of the βIII 
isoform has previously been implicated as a mechanism of 
paclitaxel resistance (Kamath et al 2005; Pusztai 2007).
While the ability to measure post translational changes 
(detyrosination and acetylation) to α tubulin has been cor-
related with microtubule stabilization and has increased 
after ixabepilone administration, this measurement does not 
correlate with clinical effectiveness of the drug (Zhuang et al 
2007). The investigators have suggested several potential 
explanations: 1) microtubule engagement is insufﬁ  cient to 
cause cell death, 2) death pathways must be activated, 3) the 
timing of post-treatment biopsies, or 4) threshold level 
of tubulin stabilization had not been reached. Tau protein 
expression, which is directly associated with estrogen expres-
sion, competes with tubulin-stabilizing agents for the same 
binding site and may confer resistance (Pusztai 2007).
Human phase I studies
Phase I data are available for: patupilone and its analogs 
(BMS-310705, sagopilone, ixabepilone), and epothilone 
D and its derivative (KOS-1584) (Table 4). The maximum 
tolerated dosages of the agents varies with the structure as 
do the toxicities. A variety of dosing schedules has been 
reported. Both dose and schedule are important in the gen-
eration of toxicities seen in man with all the epothilones 
studied to date.
Various schedules for the epothilones have been studied 
in order to modify adverse effects with varying degrees of 
success. The most distressing adverse effect is neurotoxicity, 
which occurs with the epothilone B analogs, but is not dose 
limiting with the epothilone D analogs (Table 4) (Fumoleau 
et al 2007). This problem is often dose limiting with taxane 
treatment (Markman 2003). Most patients in the published 
epothilone trials were previously treated with a taxane or 
platinum agent and thus may have had pre-existing clinical 
or subclinical neuropathy. Past studies have indicated that 
Cpmax of drugs may correlate with toxicities such as neuro-
toxicity or cardiotoxicity (Abraham et al 2003). Therefore, 
schedules that distribute the drug over time, such as a weekly 
or daily regimens, or prolonged infusion times have been 
investigated (Awada et al 2001; Burris et al 2002; Hao et al 
2002; Abraham et al 2003; Spriggs et al 2003; Rubin et al 
2005; Shimizu et al 2008).
Patupilone
Phase I studies have reported a variety of dosing schedules 
using a 5 minute bolus administration once weekly, adminis-
tered 6 of 9 weeks, or 3 of 4 weeks, or once every 3 weeks, or 
daily for 5 days as a prolonged infusion (Table 4). Patupilone 
does not demonstrate schedule-dependent myelosuppression. 
It has not been associated with hypersensitivity reactions 
and may be administered with a shorter infusion time than 
the taxanes (Rubin et al 2005). In the weekly administra-
tion schedule, patients generally tolerated doses from 0.5 to 
1.85 mg/m2 at the 6 of the 9 week schedule. At 3.6 mg/m2, 
patients experienced grade 3 diarrhea that resolved at a lower 
dose level of 2.5 mg/m2. Since diarrhea was prominent at 
the fourth week of treatment on this schedule, the regimen 
was modiﬁ  ed to 3-weekly treatments followed by 1 week 
rest with most patients tolerating 2.5 mg/m2. Dose-limiting 
toxicity was diarrhea. Other common side effects with this 
regimen included nausea, vomiting, diarrhea, and fatigue. 
Few patients experienced grade 3 or 4 myelosuppression 
(Rubin et al 2005; Schmid et al 2005).
A dose-finding study with dosages ranging 0.3 to 
8 mg/m2 every 3 weeks arrived at a dose of 6 mg/m2 for 
phase II studies. Dose-limiting toxicity was diarrhea at a 
dosage of 8 mg /m2. Other grade 3 toxicities included fatigue, 
nausea, and vomiting. Grade 2 peripheral neuropathy was 
noted in 3 of 42 patients (Calvert et al 2001). Despite dose-
limiting diarrhea, more studies are ongoing at an increased 
dosage of 6.5 to 11 mg/m2 for nonsmall cell lung cancer, 
employing an intensive bowel regimen to prevent diarrhea 
(Fumoleau et al 2007). Drug disposition is non-renal with 
no evidence of drug accumulation on repeated dosing. The 
drug is metabolized by the enzyme carboxylesterse-1 (Rubin 
et al 2005).Biologics: Targets & Therapy 2008:2(4) 797
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BMS-310705
In contrast to patupilone, this second generation derivative 
is water soluble (Table 1). The drug has been studied as a 
15-minute infusion every 3 weeks, or weekly for 3 weeks 
(Table 4). No dose limiting toxicity was noted at 40 mg/m2. 
Dose limiting toxicity of grade 4 hyponatremia secondary 
to nausea and vomiting, and grade 4 neutropenia occurred 
at 70 mg/m2. Hypersensitivity reactions were not observed. 
Common grade 1 side effects included fatigue, alopecia, 
neuropathy, nausea, constipation, myalgia, chills, and 
arthralgia. Partial responses to BMS-310705 were seen in 
one patient with ovarian cancer treated with 40 mg/m2 and 
one patient with bladder cancer treated with 30 mg/m2 out 
of a total of 59 patients (Table 4). A complete response was 
seen in one patient with nonsmall cell lung cancer at a dosage 
level of 40 mg/m2 (Mekhail et al 2003).
Ixabepilone
This agent is the most mature epothilone analog in develop-
ment (Table 4). With the weekly infusions over 30 minutes, 
there was cumulative sensory neuropathy. Investigators 
suggested that prolonging infusion time and employing 
treatment breaks with 3 weeks of treatment followed by 
1 week rest may allow patients to better tolerate this agent 
and continue treatment longer (Burris et al 2002). Heavily 
pretreated patients were more apt to experience dose-limiting 
toxicities (Hao et al 2002). Dose ranging studies evaluated 
prolonged infusion schedules: 7.5 to 65 mg/m2 administered 
over 1 hour every 3 weeks, and 15 to 50 mg/m2 administered 
over 3 hours every 3 weeks (Table 4) (Spriggs et al 2001; 
Aghajanian et al 2007; Shimizu et al 2008).
This agent, dissolved in polyethoxylated caster oil 
(Cremophor EL®), is associated with a low, but signiﬁ  cant 
risk of hypersensitivity reactions (Aghajanian et al 2007). As 
a consequence, premedication with antihistamines is required. 
Some investigators have used corticosteroid prophylaxis in 
addition (Mani et al 2004; Gadgeel et al 2005; Faivre et al 
2008). Corticosteroids may interfere with antitumor effect 
and are not recommended by the manufacturer, unless signiﬁ  -
cant hypersensitivity reactions are noted. Grade 3–4 toxicities 
were initially noted at doses over 40 mg/m2 with the most 
prominent side effects of neutropenia, myalgia, arthralgia, 
sensory neuropathy, fatigue, and nausea. The maximum tol-
erated dose was determined to be 50 mg/m2 every 3 weeks. 
Some patients who had experienced sensory neuropathy 
recovered to baseline or to less than grade 1 usually after 
2 cycles of treatment (Mani et al 2004). Grade 3–4 neuropa-
thy occurred in 7% to 19% of patients receiving 40 mg/m2 
every 3 weeks while those receiving daily ixabepilone for 
3 or 5 days had grade 3 neurotoxicity of 0% to 3%. With 
this schedule change that decreased severe neuropathy, more 
patients experienced signiﬁ  cant diarrhea. Other grade 3 
nonhematologic toxic effects included fatigue, anorexia, and 
stomatitis. Peripheral neuropathy was mild (Abraham et al 
2003; Zhuang et al 2005). Although no formal study has been 
reported in patients with hepatic compromise, the manufac-
turer advises caution when using this agent in such patients. 
This recommendation is based on the known metabolism of 
these agents as previously discussed. Ixabepilone has been 
studied by the oral route in a phase I–II trial but no data have 
been presented to date.
Ixabepilone has been combined with liposomal doxorubi-
cin and also with irinotecan with responses noted in heavily 
treated patients (Table 4). Toxicities reﬂ  ected the agents 
administered. Additional combination studies are ongoing 
and listed by http://clinicaltrials.gov, but not reported in 
abstract or in manuscript form at this time.
Epothilone D
A murine model suggested that optimal administration of 
this agent would occur with prolonged infusion (Holen 
et al 2004). Therefore, prolonged infusion times of 24 and 
72 hours administration were evaluated (Table 4). Because 
of a rapid alpha distribution of epothilone D suggesting 
rapid tissue uptake, loading doses of the drug were given 
to maintain a steady state plasma drug concentration. Grade 
3 neurotoxicity was reported at 6 mg/hour in the 24-hour 
continuous infusion cohort. Other observed adverse effects 
included fatigue, nausea, abdominal pain, and dizziness. 
One patient with bladder cancer had a decrease of primary 
nodal metastasis, and 1 patient with prostate cancer expe-
rienced a 25% decline of plasma prostate speciﬁ  c antigen 
(Table 4) (Holen et al 2004). Other schedules studied 
included once every 3 weeks and day 1–3 consecutive 
dosing. Neurological toxicity occurred more frequently 
in patients who received a large single dose of 150 mg/m2 
compared with patients who received a daily schedule for 
3 days. Neurotoxicity was most apt to be seen 1 to 2 days 
postinfusion and resolved in 2 to 7 days. This toxicity 
did not seem to be cumulative in these early trials. Mild 
neutropenia and anemia also occurred (Piro et al 2003). 
Another schedule evaluated was 16 to 100 mg/m2 given 
day 1, 8, 15 every 4 weeks. Toxicities were reported as 
mild to moderate, including fatigue, nausea and vomiting, 
and sensory neuropathy (Spriggs et al 2003). Interest in 
this drug has diminished as the newer analog KOS-1584 is Biologics: Targets & Therapy 2008:2(4) 800
Cheng et al
a more attractive compound based on its water solubility 
and preclinical activity.
KOS-1584
Dose-ranging studies of 0.8 to 11.3 mg/m2 administered over 
3 hours every 3 weeks were performed in 27 patients with 
solid tumors (Table 4) (Villalona-Calero et al 2006). Another 
study evaluated dosages of 0.8 to 25 mg/m2 given days 1, 8, 
15 every 4 weeks (Stopeck et al 2006). Studies reported side 
effects that were not dose dependent and included diarrhea, 
constipation, nausea, fatigue, and elevated aspartate trans-
aminases. Neurotoxicity was not signiﬁ  cant. Stable disease 
was noted in some patients enrolled in the phase I trial. Dose 
related increases in polymerized microtubules in peripheral 
blood mononuclear cells were observed. The percentage of 
polymerized microtubules ranged from 20% at a dose of 
0.8 mg/m2 to 40% to 50% at a dose of 8.5 mg/m2. Of note, at 
a dose of 5 mg/m2 the amount of polymerized microtubules 
reached 48%, suggesting that a plateau of polymerization 
effect occurs at clinical dosages (Stopeck et al 2006).
Sagopilone
This analog is a fully synthetic epothilone and is not a 
substrate for P-glycoprotein (Hoffmann et al 2008). Infor-
mation about this agent remains sparse although http://
clinicaltrials.gov lists several trials. A dose ranging study of 
0.6 to 29 mg/m2 administered over 30 minutes every 3 weeks 
demonstrated dose-limiting toxicity: ataxia at 16 mg/m2, 
and neuropathy at 29 mg/m2. Partial responses were seen in 
extensive small cell lung cancer and in 2 patients with breast 
cancer previously treated with a taxane (Table 4) (Schmid 
et al 2005; Gauler et al 2008).
Phase II data
The available phase II data are summarized by tumor type 
in Table 5. The largest number of trials reported involved 
the administration of ixabepilone either as a single agent or 
in combination with other established agents.
Ixabepilone has been widely studied for metastatic breast 
cancer with or without prior taxane exposure using a variety 
of schedules (Table 5). The response rates for patients without 
prior taxane exposure range from 41.5% to 57% (Denduluri 
et al 2007; Roche et al 2007). The response rates were lower 
for relapsed or refractory patients who had failed to respond 
to taxane treatment (11.5% to 22%) (Low et al 2005; Perez 
et al 2007; Thomas et al 2007a).
Response rates increased in the taxane resistant patients 
with the addition of capecitabine to ixabepilone, or the 
addition of trastuzumab with ixabepilone for Her2+ breast 
cancer patients (Moulder et al 2007; Thomas et al 2007b). 
These studies suggest that this agent can be combined 
with known effective drugs commonly used with taxane 
therapy.
One single arm phase II trial, initially presented in abstract 
form (Perez et al 2007), has led to US Food and Drug Admin-
istration (FDA) approval for commercial use in heavily 
treated breast cancer patients who had failed to respond to 
anthracyclines, taxanes, and capecitabine (Lechleider et al 
2008). In the updated report, 126 patients from 36 centers 
with prior drug resistance, and at least one evaluable lesion 
by imaging, Karnofsky performance status  70, and normal 
organ function were treated with ixabepilone at 40 mg /m2 
administered as an intravenous infusion once every 3 weeks. 
Independent review committee response evaluation of the 
113 study patients determined a 12.4% partial response rate 
with a median time to response of 6.1 weeks and an average 
duration of response of 6 months (5 to 7.6 months, 95% 
conﬁ  dence limits) (Lechleider et al 2008).
One ongoing study is evaluating epothilone B in the 
setting of metastatic breast cancer patients with brain metas-
tases, progressing after whole brain radiation therapy, with 
1 out of 12 patients demonstrating a partial response (Conlin 
et al 2008). The grade 3–4 toxicities reported were mainly 
gastrointestinal.
Patupilone has been evaluated in patients with metastatic 
carcinoid and related neuro-endocrine tumors (Table 5). 
Preliminary data demonstrate disease stabilization with grade 
3–4 gastrointestinal side effects (Anthony et al 2003).
Advanced colon cancer patients refractory to at least one 
prior chemotherapy containing 5-ﬂ  uorouracil, irinotecan, 
and leucovorin (IFL) did not respond to ixabepilone (Eng 
et al 2004). Patupilone treatment in 47 patients with colon 
cancer on a once weekly for three weeks schedule every 
28 days noted only 1 partial response but was associated with 
signiﬁ  cant toxicity (Table 5) (Poplin et al 2003).
A study of metastatic gastric cancer patients treated 
with ixabepilone at 50 mg/m2 administered once every 
21 days resulted in a 9% response rate (2 out of 23 patients) 
(Ajani et al 2006). No response was seen in patients who 
received ixabepilone 6 mg/m2 for 5 days, possibly related 
to low plasma drug concentrations with this divided dosing 
schedule. Grade 3 to 4 neuropathies in the 50 mg/m2 cohort 
and 6 mg/m2 cohort were statistically different (8% vs 4%) 
(Ajani et al 2006). In another study of locally advanced or 
metastatic gastric cancer patients, patupilone demonstrated 
a partial response rate of 9% of patients and a combined Biologics: Targets & Therapy 2008:2(4) 801
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Novel microtubule-targeting agents – the epothilones
response and disease stabilization rate of 36% (Hsin et al 
2006).
Ixabepilone was evaluated in hepatobiliary cancer and 
while there were partial responses and disease stabilization, 
the magnitude of the anticancer effects was deemed to be 
not clinically signiﬁ  cant (Singh et al 2006).
Ixabepilone has been a disappointment in metastatic germ 
cell tumors refractory to cisplatin therapy. Only 12 patients 
were entered into the study with 1 partial response in a taxane 
naive patient. The time to progression was 2 weeks, and the 
study was terminated (Table 5) (Feldman et al 2007).
Sagopilone was believed to be a good candidate for 
evaluation in human brain tumors based upon preclinical 
data and absence of perturbation of in vitro efﬁ  cacy by the 
P-glycoprotein resistance protein (Alexander et al 2008; 
Hoffmann et al 2008). However, in phase II trials for 
recurrent malignant gliomas and recurrent glioblastomas, 
this agent demonstrated disease stability of only 6 to 
13 weeks duration (Table 5) (Silvani et al 2008; Stupp 
et al 2008).
For gynecologic cancers, preliminary data in patients 
with advanced ovarian cancer who did not respond to prior 
platinum drugs demonstrated a 10% response rate (Smit et al 
2005). Ixabepilone has also shown responses in ovarian and 
endometrial cancer patients previously treated with taxanes 
(Table 5) (Chen et al 2004).
In head and neck cancer, ixabepilone was studied in two 
regimens: 1) treatment on days 1 to 5 repeated every 21 days, 
or 2) weekly dosing. Burtness et al (2006) also stratiﬁ  ed 
patients with metastatic or recurrent squamous cell cancer 
of the head and neck on the basis of being taxane naïve or 
having prior taxane exposure. Partial responses were seen 
in the taxane-naïve patient group using the weekly regimen 
(Table 5). Lower rates of sensory and motor neuropathy 
were noted in the 5-day dosing regimen compared with the 
weekly regimen in both taxane-naïve and exposed groups 
(Burtness et al 2006).
Preliminary data show activity of ixabepilone in indolent, 
mantle cell lymphoma, and aggressive non-Hodgkin’s 
lymphoma (O’Connor et al 2005; Smith et al 2005). Ixabepi-
lone is not an effective treatment in Stage IV melanoma while 
sagopilone demonstrated responses in 2 out of 14 patients 
who had previously failed dacarbazine or temozolamide 
(Pavlick et al 2004; Wenk et al 2008). Ixabepilone and 
KOS-862 have shown responses in non-small cell lung cancer 
that failed prior platinum (Yee et al 2005; Vansteenkiste 
et al 2007). Ixabepilone did not show signiﬁ  cant responses 
in children and adults with refractory pediatric tumors 
(Jacobs et al 2008). Ixabepilone has also been noted to have 
activity in soft tissue sarcoma (Okuno et al 2005).
In patients with prostate cancer that was castrate resistant 
and taxane refractory, patupilone, ixabepilone, and KOS-862 
have all decreased prostate speciﬁ  c antigen levels (Beer et al 
2007; Rosenberg et al 2007; Chi et al 2008). In patients with 
castrate refractory metastatic prostate cancer tumors, but not 
chemotherapy-resistant tumors, patupilone, ixabepilone, and 
sagopilone induced prostate-speciﬁ  c antigen declines (Hus-
sain et al 2004, 2005; Graff et al 2008).Ixabepilone has been 
studied in different dosing regimens with the once every 21 
days dosing schedule compared with days 1, 8, 15 dosing 
every 28 days. Higher rates of grade 3–4 sensory neuropa-
thy and neutropenia occurred in the days 1, 8, 15 regimen 
(Hussain et al 2005; Wilding et al 2008). The addition of 
estramustine to ixabepilone increased the response rate 
compared with ixabepilone alone (response rate 69% vs 48% 
respectively) (Galsky et al 2005).
Unlike most ixabepilone dosing regimens demonstrat-
ing better responses with the once every 21 day regimen, 
metastatic renal cell carcinoma treated with this schedule 
had stable disease as the best response (Posadas et al 
2007). In this tumor, ixabepilone was administered on days 
1 to 5 every 21 days or on days 1, 8, 15 with a cycle length 
of 28 days. Both regimens demonstrated responses (Fojo 
et al 2005; Burtness et al 2006; Huang et al 2008). Patu-
pilone has also been shown to have activity in metastatic 
renal cell carcinoma (Thompson et al 2003). Ixabepilone 
also has activity in advanced urothelial cancer (Dreicer 
et al 2007).
Phase III trials
Only one completed open label phase III trial has been 
presented and published at the time of this review. This study 
was a multi-institution collaboration involving 160 multi-
national sites. Ixabepilone combined with capecitabine was 
compared with capecitabine alone in a cohort of female 
patients with metastatic or locally advanced breast cancer, 
previously exposed to taxanes and anthracyclines (Thomas 
et al 2007b). Patients who had progression of their tumor 
during treatment, or within 3 months of prior treatment, or 
had a recurrence of their tumor within 6 months of adjuvant 
or neo-adjuvant treatment after exposure to anthracyclines 
and taxanes were eligible. The entry criteria were modiﬁ  ed 
after 377 patients were enrolled to allow progression within 
4 months of treatment or within 12 months of adjuvant/neo-
adjuvant therapy. Patients with known brain metastasis, 
end organ dysfunction, or National Cancer Institute CTC Biologics: Targets & Therapy 2008:2(4) 808
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criteria of neuropathy  grade 2 were excluded. Further 
exclusions included hypersensitivity to the study drugs, use 
of cytochrome P450 3A4 inhibitors, and known or suspected 
dihydropyrimidine dehydrogenase (involved in ﬂ  uorouracil 
metabolism) deﬁ  ciency. Ixabepilone was administered as an 
intravenous infusion at 40 mg/m2 over 3 hours every 21 days. 
In the combination arm, capecitabine was administered orally 
at 2000 mg/m2 in 2 divided daily doses for 14 days every 
21 days or in the single agent comparator arm capecitabine 
at 2500 mg/m2 in 2 divided daily doses for 14 days on a 21-
day cycle (Thomas et al 2007b).
The median age of study patients was 53 with a range 
of 25 to 79 years. Approximately two-thirds were hormone 
receptor positive, 15% of patients had Her2 positive 
tumors, 84% had visceral disease, and 92% of patients 
received protocol therapy as second or third line treatment 
for metastatic disease. The combination demonstrated 
a superior progression-free survival (hazard rate 0.75, 
p = 0.003) of 5.8 months compared with 4.2 months for 
capecitabine alone. Independent review of responses noted 
35% of patients achieved response in the combination arm 
vs 14% of patients in the monotherapy arm (p  0.0001). 
Peripheral neuropathy was noted in 65% of patients in the 
combination arm with grade 3 neuropathy in 20% and grade 
4 in 1%. Of the patients receiving the combination arm, 
21% discontinued therapy after a median of 6 cycles due 
to grade 3–4 peripheral neuropathy. Myelosuppression was 
also noted in the ixabepilone arm with a 5% incidence of 
febrile neutropenia (Thomas et al 2007b). Twenty percent 
of patients on the combination arm required growth factor 
support. An updated report of this study with a reanalysis of 
the progression-free survival indicated the median progres-
sion free survival in the combination arm was 5.7 months 
compared with 4.1 months in the monotherapy arm (Thomas 
2008). On the basis of this trial, ixabepilone was approved 
by the FDA for commercial use in the US (Lechleider et al 
2008).
Conclusions
Epothilones have potent preclinical and clinical activity 
in human malignancies. As such, they represent new enti-
ties that need to be integrated into cancer treatment. Early 
studies indicate that drugs of this class have broad activity 
in many of the human tumor types. These agents have a 
preclinical rationale to offer an advance over taxane therapy 
and in early human phase I–II trials have noted responses 
in patients believed to be taxane resistant. However, their 
distinction from the more commonly used taxane drugs in 
the treatment of clinical disease will require a randomized 
phase III trial of an epothilone vs. taxane as primary therapy 
for metastatic disease. No such trial has been reported. 
This concern is not a trivial issue as the US Medicare 
reimbursement for a single treatment with paclitaxel at 
175 mg/m2 for a patient of 1.7 m2 is US$570 per treatment 
and for ixabepilone at 40 mg/m2 for the same patient is 
US$17,615.
The role of P-glycoprotein resistance protein as a primary 
mechanism of clinical refractoriness of tumors to anticancer 
therapy is a controversial area. The major difference between 
epothilones and taxanes is the ability of epothilones to 
be unaffected by the P-glycoprotein resistance pump. As 
previously mentioned, speciﬁ  c subgroups of solid tumors 
such as the Her2 positive breast cancers may be a particularly 
important target for this class of agents. Other mechanisms 
of resistance are also thought to be important in the manage-
ment of solid tumors.
The epothilones such as ixabepilone and sagopilone, 
analogous to taxanes, exhibit neurologic toxicity. Although 
changes in the dosing schedule, decreasing the maximum 
plasma concentration, and prolonging infusion to lessen 
Cpmax may diminish neurological adverse effects, such 
treatments have shifted the dose limiting toxicity from 
neurological to gastrointestinal adverse events. These 
toxicities in part may reﬂ  ect the heavily pretreated population 
exposed in the initial studies to these agents. Data on the 
efﬁ  cacy and toxicity of the various epothilone analogs as 
primary therapy in humans is urgently needed as the toxicities 
in this group of patients may be markedly less.
The epothilone structure does allow semisynthetic and 
fully synthetic production of the agent. In addition, the 
chemical structure is more amenable to modiﬁ  cation than is 
paclitaxel. As a consequence, there are a plethora of analogs 
which are undergoing evaluation (Altmann and Memmert 
2008). The ability to modify the chemical structure also 
allows the solubility and stability of the agent to be adjusted 
for human use. In addition, the structure allows modiﬁ  ca-
tions that signiﬁ  cantly differ from the parent compound and 
yet allow the resulting compounds to remain tubulin binders 
(Feyen et al 2008). At present, epothilone D is not being 
actively clinically investigated.
Ixabepilone is the most clinically developed of the analogs 
and has received commercial approval in the US for treatment 
of refractory breast cancer. This approval is on the basis of 
efﬁ  cacy in clinically taxane resistant breast cancer as a single 
agent and in combination with capecitabine. Combination of 
epothilones with either classical cytotoxics or with biologics Biologics: Targets & Therapy 2008:2(4) 809
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are currently in progress and will serve to further deﬁ  ne the 
role of these drugs in the treatment of cancer.
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